- Query in any language with multilingual search
- Access EUR-Lex and EU Commission case law
- See relevant paragraphs highlighted instantly
Similar Documents
Explore similar documents to your case.We Found Similar Cases for You
CSL / NOVARTIS INFLUENZA VACCINES BUSINESS
M.7583
With us you find everything. Try it now!
I imagine what I want to write in my case, I write it in the search engine and I get exactly what I wanted. Thank you!
Valentina R., lawyer
Disclaimer :
The Competition DG makes the information provided by the notifying parties in section 1.2 of Form CO available to the public in order to increase transparency. This information has been prepared by the notifying parties under their sole responsibility, and its content in no way prejudges the view the Commission may take of the planned operation. Nor can the Commission be held responsible for any incorrect or misleading information contained therein.
SECTION 1.2
Description of the concentration
1.This notification relates to the proposed acquisition of sole control of Novartis’s human influenza vaccines business by CSL Limited within the meaning of Article (3)(1) of the Merger Regulation.
The business in which the Parties are engaged is:
CSL is a pharmaceutical company active worldwide in research, development, manufacturing and marketing of biotherapies, vaccines (via its subsidiary bioCSL) and other pharmaceuticals.
Novartis is a diversified healthcare company. In Europe, the Novartis business includes:
•• Novartis Pharmaceuticals.
•• Alcon, specialising in eye care medicines.
•• Sandoz, specialising in generic medicines.
Commission européenne, DG COMP MERGER REGISTRY, 1049 Bruxelles, BELGIQUE Europese Commissie, DG COMP MERGER REGISTRY, 1049 Brussel, BELGIË
Tel: +32 229-91111. Fax: +32 229-64301. E-mail: COMP-MERGER-REGISTRY@ec.europa.eu.